Evidence map›Paper›PMID 22107967›Full record

ArticleJournal of immunological methods2012

The use of Bcl-2 over-expression to stabilize hybridomas specific to the HERG potassium channel.

Jakub Sroubek, Yamini Krishnan, Jordan Chinai, Susan Buhl, Matthew D Scharff, Thomas V McDonald

Abstract read
In one paragraph

Article in Journal of immunological methods, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jakub SroubekDepartment of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY 10461, United States.
Yamini Krishnan
Jordan Chinai
Susan Buhl
Matthew D Scharff
Thomas V McDonald
Albert Einstein College of Medicine · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007288 · NIGMS · YESHIVA UNIVERSITY · PI AKABAS, MYLES H. · 1985 to 2022
$35.6M
Adrenergic Regulation of HERG ProteinR01HL077326 · NHLBI · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI MCDONALD, THOMAS V · 2004 to 2007
$1.6M
Structure-function Analysis of KCNE Interactions with Cardiac Channels KCNQ1 & HER01HL093440 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI MCDONALD, THOMAS V · 2010 to 2013
$1.6M
NHLBI NIH HHS HL077326NHLBI NIH HHS HL093440NHLBI NIH HHS R01 HL077326NHLBI NIH HHS R01 HL093440NIGMS NIH HHS T32 GM007288
6 · The paper itself

Abstract

We encountered a high degree of clonal hybridoma loss in the course of generating antibodies specific for the hERG potassium channel. A protein that is crucial for controlling heart rhythm, is abundant in parts of the brain and is abnormally expressed in some tumors. Intracellular domains of the protein were used for immunogens and generated adequate antibody responses in mice. Subsequent hybridomas created using Ag8 myeloma fusion partner yielded clones that secreted specific antibody but none could be successfully maintained in culture. A variety of mechanisms, including polyploidy inherent to hybridoma development or production of cytotoxic antibodies, may be responsible for eventual loss of cell viability by mechanisms that may include apoptosis. When spleen cells were fused to the NSO myeloma cell line that stably over-expresses the anti-apoptotic protein Bcl-2, hybridoma clones were generated that remained viable in culture with high level of hERG-specific antibody production. When the parental NSO cell line not over-expressing Bcl-2 was used, no stable hybridomas were produced. Antibodies secreted by NSO-Bcl-2 hybridomas were specific for hERG and performed well in immunoblot, immunoprecipitation and immunofluorescence assays. This work demonstrates a feasible option when faced with antigens that seem to be associated with clonal instability in the process of generating monoclonal antibodies.

Indexed as

AnimalsAntibodies, MonoclonalApoptosisApoptosis Regulatory ProteinsCell Line, TumorCell SurvivalERG1 Potassium ChannelEther-A-Go-Go Potassium ChannelsFemaleHEK293 CellsHumansHybridomasMiceMice, Inbred BALB CMultiple MyelomaProto-Oncogene Proteins c-bcl-2Antibodies, MonoclonalApoptosis Regulatory ProteinsERG1 Potassium ChannelEther-A-Go-Go Potassium ChannelsKCNH2 protein, humanProto-Oncogene Proteins c-bcl-2

Identifiers

PMID22107967
PMCPMC3253882
OpenAlexW2122544518

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.